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Background: Feline Immunodeficiency Virus (FIV) is a viral pathogen that infects domestic cats and wild felids.
During the viral replication cycle, the FIV p15 matrix protein oligomerizes to form a closed matrix that underlies the
lipidic envelope of the virion. Because of its crucial role in the early and late stages of viral morphogenesis,
especially in viral assembly, FIV p15 is an interesting target in the development of potential new therapeutic
strategies.
Results: Our biochemical study of FIV p15 revealed that it forms a stable dimer in solution under acidic conditions
and at high concentration, unlike other retroviral matrix proteins. We determined the crystal structure of full-length
FIV p15 to 2 Å resolution and observed a helical organization of the protein, typical for retroviral matrix proteins. A
hydrophobic pocket that could accommodate a myristoyl group was identified, and the C-terminal end of FIV p15,
which is mainly unstructured, was visible in electron density maps. As FIV p15 crystallizes in acidic conditions but
with one monomer in the asymmetric unit, we searched for the presence of a biological dimer in the crystal. No
biological assembly was detected by the PISA server, but the three most buried crystallographic interfaces have
interesting features: the first one displays a highly conserved tryptophan acting as a binding platform, the second
one is located along a 2-fold symmetry axis and the third one resembles the dimeric interface of EIAV p15. Because
the C-terminal end of p15 is involved in two of these three interfaces, we investigated the structure and assembly
of a C-terminal-truncated form of p15 lacking 14 residues. The truncated FIV p15 dimerizes in solution at a lower
concentration and crystallizes with two molecules in the asymmetric unit. The EIAV-like dimeric interface is the only
one to be retained in the new crystal form.
Conclusion: The dimeric form of FIV p15 in solution and its extended C-terminal end are characteristic among
lentiviral matrix proteins. Crystallographic interfaces revealed several interactions that might be involved in FIV
replication. Further studies are needed to better understand their biological relevance in the function of FIV Gag
during viral replication.
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The Feline Immunodeficiency Virus (FIV) is an enveloped
virus from the family Retroviridae, genus lentivirus, which
also contains the human immunodeficiency virus
(HIV), equine infectious anemia virus (EIAV) and simian
immunodeficiency virus (SIV). FIV infection induces an* Correspondence: christophe.guillon@ibcp.fr
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reproduction in any medium, provided the orimmunodeficiency syndrome in infected domestic cats
or wild felids, which resembles HIV-induced AIDS.
Therefore, this syndrome has been dubbed feline
AIDS. FIV is an important veterinary issue as it infects
up to 30% of domestic cats in some parts of the world
with apparently no evolution of host resistance [1,2].
Moreover, FIV has been described as a useful model for
the development of AIDS vaccines, antiretroviral drugs,
and non-pathogenic gene therapy vectors [3,4]. However,
compared to primate lentiviruses, many fundamental
aspects of FIV biology are not well understood, and noLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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viral enzymes, the dUTP-pyrophosphatase [5], and the
protease [6,7].
Matrix protein (MA), p15 in FIV or EIAV and p17 in
HIV or SIV, is the N-terminal subunit of the retroviral
Gag polyprotein. This Gag polyprotein is involved in the
architecture of the viral particle, which is common to
HIV and FIV and is essential for infectivity of the virus
[8-10]. The MA subunit of Gag is also involved in
recruiting the viral envelope glycoproteins onto virions
[8-10]. In FIV, HIV or SIV, the N-terminal domain of
Gag undergoes a co-translational covalent modification
of the MA N-terminus with a myristoyl group [11-15].
This myristoylation, together with a highly basic patch
of amino acid residues located at the N-terminus of the
MA, directs the Gag polyprotein to the plasma membrane
(PM), mediating the association between Gag and the
inner leaflet of the PM lipid bilayer, where Gag forms a
hexagonal network [16]. The N-terminal end of Gag for
some retroviruses, including EIAV, is not myristoylated,
and some N-terminal ends bear a different chemical
modification [17,18]. Interestingly, FIV appears to be an
exception among nonprimate lentiviruses because of its
capacity to be myristoylated [19].
After the budding of virus particles from host cells, the
Gag polyprotein is cleaved by the viral protease into its
different subunits during maturation [20]. In the mature
particle, the capsid and the nucleocapsid subunits of the
Gag polyprotein make a compact RNA-containing conically
shaped capsid inside the virion, in contrast to the MA
protein, which remains at the inner surface of the virus
membrane.
In the HIV model, the N-terminal myristoyl group of
MA can adopt sequestered and exposed conformations
[21] consistent with a myristoyl switch mechanism for
regulating membrane binding [22-25]. The formation of
MA trimers in HIV can trigger the myristoyl switch [21].
While HIV MA proteins associate in solution and in crystal
structures as trimers, they organize onto membranes in
a hexamer arrangement [26]. These observations have
led to the suggestion that the MA trimers incorporate
into Gag hexamers, with the trimers forming nodes that
interconnect the hexamers [27].
Previous studies have determined the three-dimensional
structure of HIV p17, SIV p17 and EIAV p15 by nuclear
magnetic resonance spectroscopy (NMR) [21,28-30] and
X-ray crystallography [13,31,32]. MA proteins appear to
be globular proteins with a compact fold made of five
α-helices. In addition, the HIV protein contains a
highly basic platform, which allows the targeting of
Gag polyproteins to the plasma membrane [14,15].
These structural studies have also demonstrated that p17
HIV and p17 SIV can form trimers [13,32]. However, some
retroviral matrix proteins, such as EIAV MA, are dimerunits in crystal structures [31,33]. In fact, these conform-
ational differences between the lentiviral proteins may be
correlated with their mode of association. Hatanaka et al.
suggested that the dimeric conformation observed for
EIAV p15 could correspond to a weakened membrane-
binding state and proposed a new alternative membrane-
binding mechanism [31]. The comparison of the atomic
structure of FIV p15 with those of matrix proteins of other
retroviruses, such as HIV or EIAV, will help to define the
specificity of the molecular mechanisms of FIV assembly.
To characterize the FIV p15 structure, we over-expressed
FIV p15. This allowed us to perform the first studies on the
oligomeric state of the FIV p15 protein and to determine
the crystal structure of full-length FIV p15. The structure
of a C-terminal-truncated FIV p15 was solved in turn to
assess the role of this region in the oligomerization
process. In conclusion, we discuss the conformational
differences observed between FIV p15 and the matrix
protein of other lentivirus. In addition, we also discuss
the possible role of the flexible C-terminus of FIV p15
in the replication cycle.
Results
Biochemical and biophysical characterization of the FIV
p15 oligomeric state
Retroviral matrix proteins oligomerize into dimers, tri-
mers or hexamers [21,26,31]. Thus, we evaluated the
oligomerization properties of FIV p15. The FIV p15
protein was analyzed by DLS (dynamic light scattering)
to determine its oligomerization state in solution at
different concentrations (3 mg/ml and 6 mg/ml) and
pH values (pH 6 and pH 7.4) (Figure 1A). A single peak
was observed in each experiment, which confirmed the
homogeneity of the protein solution. At 6 mg/ml, the
average diameter of the FIV p15 protein in 50 mM sodium
phosphate pH 7.4 was 4.3 nm with a standard deviation
of 0.2 nm (Figure 1A). This value is consistent with a
monomeric form of FIV p15 [34]. In contrast, the protein
in 50 mM MES pH 6 presented an average diameter of
5 nm and a standard deviation of 0.1 nm (Figure 1A),
suggesting that the protein was mainly in its dimeric form
at 6 mg/ml in this more acidic buffer. This was confirmed
by cross-linking experiments on the same samples using
bis(sulfosuccinimidyl)suberate (BS3). These experiments
demonstrated that the FIV p15 protein in 50 mM sodium
phosphate pH 7.4 was mainly monomeric, whereas a
dimeric state was observed for the protein in 50 mM MES
pH 6 (Figure 1B). These results are in a good agreement
with our experimental data obtained by DLS. It is
noteworthy that the protein was monomeric in both
buffers at a lower concentration (3 mg/ml in 50 mM
sodium phosphate pH 7.4 or 3.3 mg/ml in 50 mM
MES pH 6, Figure 1B). Thus, the oligomeric state of
FIV p15 protein depends both on the buffer and the





Figure 1 Analysis of the oligomeric state of the p15-His protein. (A) DLS spectrogram obtained with the p15-His protein at 3 and 6 mg/ml
in 50 mM sodium phosphate pH 7.4 buffer (left curves) and 50 mM MES pH 6 buffer (right curves), respectively. (B) Chemical cross-linking with
BS3 of p15 with or without 6-His tag. Lanes 1 to 4: p15-His at-3.3 and 3 mg/ml (lane 1 and 2) or 6 and 6.5 mg/ml (lane 3 and 4), in 50 mM MES
pH 6 buffer (lane 1 and 3) and 50 mM sodium phosphate pH 7.4 buffer (lane 2 and 4). Lanes 5 and 6: p15 without 6-His tag at 6 mg/ml in
50 mM sodium phosphate pH 7.4 buffer (lane 5) or 50 mM MES pH 6 buffer (lane 6). M is the molecular weight marker. The asterisk indicates the
expected size for the dimeric form. (C) The SEC-MALLS spectra of the molecular weight (dotted line) and absorbance at 280 nm (plain lines)
versus elution volume. The p15 protein in 50 mM MES pH 6 buffer and at 6 mg/ml was loaded into the column. (D) Dissociation constant of the
p15-His dimer measured by ITC. The thermogram (top panel) and the plotted titration curve (bottom panel) were obtained with a Microcal
ITC200. The solid line (bottom panel) represents the fitting of the data by the built-in dimer dissociation model.
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dimeric state when the acidity of the buffer and the
protein concentration increase. The presence of the
histidine tag was not responsible for the formation of
the dimeric form, as the protein without the tag was
also dimeric at 6 mg/ml in MES buffer (Figure 1B).
We confirmed this oligomeric behavior of p15 in solution
by submitting a sample of his-tagged protein at 6 mg/ml
in 50 mM MES pH 6 to SEC-MALLS (size-exclusion
chromatography with multi-angle laser light scattering)(Figure 1C). The FIV p15 protein was eluted as a single
peak from the gel-filtration column, demonstrating a
single oligomeric state of the protein. According to the
refracting index and the light scattering measurements,
this oligomer had a MW value approximately 36,000 Da
(Figure 1C), confirming the presence of dimers. These
data demonstrated that FIV p15 is in a dimeric conform-
ation in solution under mild acidic conditions and at a
high protein concentration. In these conditions, the
dissociation constant (Kd) of this dimer was measured
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around 10 μM (Figure 1D).Structure determination of the FIV full-length p15 protein
by X-ray crystallography
FIV full-length p15 protein at 6 mg/ml in MES buffer
pH 6 crystallizes in the presence of sodium acetate pH 4.6
and PEG in the space group P21212 with one molecule in
the asymmetric unit. Synchrotron data were collected to
2 Å resolution. The phase problem was solved by molecular
replacement using SIV p17 (PDB ID: 1ECW) as the search
model [32]. The FIV p15 structure was refined to a final





Data collection temperature (K) 100
Space group P212
Unit cell parameters a =
α =
Matthews coefficient /% solvent 1.89
Resolution range (Å) 20-2
Total number of reflections 52,8
Number of unique reflections 7,64
Rsym (%) 9.2




Resolution range (Å) 19.3
Number of unique reflections 7,64
Rwork (%) 19.0
Rfree (%) 24.6
Number of protein atoms 1,03
Number of water/ethylene glycol molecules/PEG molecules 28/4
Mean B-factor (Å2) 19.4
Coordinate deviations
RMSD bond lengths (Å) 0.00






Outermost shell values are indicated in parentheses.The structure consists of five α-helices (numbered h1 to
h5 following the HIV convention), which give rise to the
close packing of adjacent helices typical for retroviral
matrix proteins (Figure 2A). The three amino-terminal res-
idues (Gly4-Gln5-Gly6) and the twenty carboxy-terminal
residues (Met113 to Gln133) are mainly unstructured and
extended (Figure 2A). Despite its intrinsic flexibility, the
C-terminal end (Met113 to Gln133) is clearly observed in
the electron density map because of the stabilizing crystal
contacts of the C-terminal residues 130 to 132 with the
complementary monomer.
An analysis of the electrostatic potential of FIV full-
length p15 revealed a highly basic platform, with helix h1
having amphipathic character (residues Arg7 to Cys16)p15 FIV p15-Δ120
ima 1 (SOLEIL, Paris) ID-29 (ESRF, Grenoble)




53.0 Å, b = 71.2 Å, c = 28.2 Å a = 28.5 Å, b = 71.3 Å, c = 57.1 Å
β = γ = 90° α = γ = 90°, β = 99.6°
/ 34.90% 1.95 / 37.05%
.0 (2.05-2.0) 20-2.7 (2.77-2.7)
97 20,503
7 (543) 6,139 (448)
(45.4) 8.1 (37.6)




1-2.0 (2.29-2.0) 19.68-2.7 (3.40-2.7)
7 (2,357) 6,138 (1,571)
5 (21.11) 21.51 (23.48)










Figure 2 Overview of the FIV p15 protein. (A) Structure of FIV p15, with the secondary structure elements colored blue-to-red from the N- to
the C-terminus and helices numbered h1 to h5. Loops l1 to l4 between the helices are represented as well as the N- and C- termini. (B) Surface
representation of the electrostatic properties of FIV p15. The electrostatic potential is shown with positive charges in blue and negative charges
in red. The arrow indicates the putative myristoyl-binding pocket of FIV p15. (C) and (D) Docking prediction of the myristoyl insertion in FIV p15
in (C) and out (D) the hydrophobic pocket. The myristoyl group is displayed as a van der Waals representation with gray spheres and its carboxyl
functional group in red. The N-terminal glycine residue is represented in magenta. The residues involved in the interaction with the myristoyl
group are labeled and displayed in yellow or orange at their initial positions and their positions after the docking experiment, respectively. The
backbone of the protein is colored as in (A). (E) The representation of the surface of FIV p15 after docking of the myristoyl group in the external
groove. Myristoyl is displayed as in (C) and (D).
Table 2 Structural comparisons with other lentiviral
matrix proteins
Protein PDB ID RMSD1 Nalign
2 %seq3
EIAV MA 1HEK 2.5 Å 99 17
HIV MA 1HIW 1.9 Å 101 18
SIV MA 1ECW 2.1 Å 105 15
1 Root Mean Square Deviation calculated between Cα-atoms of
matched residues.
2 Number of aligned residues after structure superimposition.
3 Sequence identity.
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the 30 N-terminal amino acids form a highly basic region
that provides a motif presumably to interact with the
acidic phospholipid head groups, as described for HIV
p17 [21,35]. This creates a strong dipole across the
molecule and a positively charged surface for membrane
interaction (Figure 2B). As with HIV, a hydrophobic cavity
formed by the side chains of helices h1 to h4 is observed in
the FIV p15 protein (Figure 2B). Our docking studies
demonstrated that a myristoyl group can be placed in this
cavity with its carboxyl end in the vicinity of the N-
terminus of p15, providing the local adjustment of resi-
dues from helices h1, h2 and h4 (Trp9, Phe35, Ile39, Ile53,
and Phe90, Figure 2C). These residues are located at
the same positions as the residues interacting with the
N-terminal myristoyl of the HIV MA (Ser9, Ile34, Ser38,
Leu51 and Leu85, respectively [21]). The estimated binding
free energy of the myristoyl group is similar for FIV
and HIV (-2.9 kcal/mol and -3.7 kcal/mol, respectively).
One striking feature, when the myristoyl group is inserted
in the hydrophobic pocket of FIV p15, is the predicted
motion of Trp9 and Ile53, which rotate from their initial
position (Figure 2C). Of interest, our docking experiments
revealed a second putative binding site for the myristoyl
group that wraps around the first turn of helix h1 (Figure 2D)
in a groove located at the surface of the protein
(Figure 2E). This location involves the interaction of themyristoyl group with residues Trp9, Ala12, Arg15, Glu55
and Leu95 of helix h1 and loops l2 and l4.
FIV p15, despite having a low sequence similarity with
HIV, EIAV and SIV MA (18%, 17% and 15% sequence
identities, respectively) is strikingly similar in structure
to these lentiviral matrix proteins and can be superposed
to each with a root mean square deviation (RMSD) of
1.9 Å, 2.5 Å, and 2.1 Å between Cα pairs, respectively
(Table 2). However, the superimposition of the lentiviral
MA structure reveals a major difference around the
C-terminal end of MA (Figure 3). The C-terminal end of
FIV p15 is mainly unstructured and extended (Figures 2
and 3), whereas a long helix h5 is observed in HIV p17
(Figure 3A), and a short β-hairpin is reported in SIV MA
(Figure 3B). The C-terminal end of EIAV p15 is not visible
in the electron density maps and is absent from its
Figure 3 Structural comparison of four lentiviral matrix protein.
The superimposition of the matrix proteins of FIV (red) with (A) HIV
(PDB ID: 1HIW, blue), (B) SIV (PDB ID: 1ECW, green) and (C) EIAV
(PDB ID: 1HEK, yellow) matrix proteins. The N- and C-termini are
indicated, and the helices are numbered h1 to h5 as in Figure 2A.
Black arrows highlight the structural differences at the C-terminal
end of the matrix proteins.
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of longer loops in FIV as compared with EIAV, HIV and
SIV because of insertions in the FIV sequence (Figure 4).
As these loops are important to the stabilization of HIV
and SIV trimers, the longer loops may be related to the
differences observed in the FIV p15 oligomerization.
There are 6 conserved residues between the proteins
(Figure 4, black squares), most of which are within the
helical sections of the molecule, and they may be
responsible for maintaining the characteristic matrix
architecture. Finally, we can observe in the structure of
FIV p15 a cluster of Phe residues (Phe30, Phe35 and
Phe90) that form a π-stacking interaction between helices
h2 and h4 (data not shown). This hydrophobic interaction
is not found in other retroviral matrix proteins and may
be implicated in the stabilization of conformation of the
FIV p15 protein [36].
Oligomeric interfaces of FIV p15 in the crystal
Because FIV p15 forms a dimer in solution at acidic
pH, and FIV p15 crystals were obtained in an acidic
crystallization condition, we performed a search for a
biological assembly in the crystal with the PISA server
[37]. No dimeric (or higher) assembly was detected.
Therefore, we more closely examined the top three
dimeric interfaces in terms of buried surface.
The first interface (interface 1) implicates the conserved
residue Trp37, localized at the center of helix h2 and the
C-terminal end of a contacting p15 monomer (Gly130 to
Pro132) (Figure 5A). The average buried surface area is
543 Å2 per monomer. Of interest, the indol group of
Trp37 makes extensive contacts with the Pro131 of the
complementary molecule via hydrophobic stacking. This
maintains the C-terminal end of FIV p15 in an extended
conformation in the crystal, which is stabilized by three
hydrogen bonds (Figure 5A and Table 3).
The second interface (interface 2) implicates an anti-
parallel assembly made up by residues of the C-terminal
end via a 2-fold symmetry axis (Figure 5B). Its average
buried surface area is 497 Å2 per monomer. The assembly
structure has bonds between three residues (Thr117-
Arg118-Glu123) and their 2-fold symmetry related
counterparts (Figure 5B and Table 3).
The third interface (interface 3) involves an interaction
between loop l3 and helix h5 from one monomer with
loop l3 and helix h4 from the other monomer (Figure 5C
Figure 4 Structure-based sequence alignment of four lentiviral matrix proteins. Alignment between FIV p15, EIAV p15, HIV p17 and SIV
p17. The conserved residues are boxed and the physico-chemical equivalent residues are on a light gray background. Helices (squiggles along
the sequence) of the crystal structures are shown for FIV p15 (this paper), EIAV p15 (PDB ID: 1HEK), HIV p17 (PDB ID: 1HIW) and SIV p17 (PDB ID:
1ECW). The alignment was performed with ESPript web server [67].
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surface area of 401 Å2 per monomer. The interface 3
resembles the interface of EIAV dimers [31] (Additional
file 1: Figures S2A & S2B). Moreover, it is the only interface
with a favorable P-value calculated by PISA [37] for the
observed solvation free energy gain (p = 0.287) compared
to interface 1 (p = 0.487) or interface 2 (p = 0.603).
To investigate which interface could be the biological
dimer that we observe in vitro, we constructed a shortened
form of FIV p15, p15-Δ120, which is truncated after
Ser120 to remove the residues involved in interface 1. The
p15-Δ120 truncated protein was stable and was still able to
generate dimers in solution in MES buffer, even at a lower
protein concentration (3 mg/ml, Additional file 1: Figure
S1A). Crystals of p15-Δ120 could be grown, and data could
be collected to 2.6 Å resolution. The crystal space group
for p15-Δ120 is different (P21) from the full-length protein
(P21212), and 2 monomers are present in the asymmetric
unit (Figure 6). The truncation of the last 14 residues does
not alter the overall conformation of the protein, as
demonstrated by the RMSD of 0.5 Å between the Cα
pairs in the truncated protein and the full-length protein.
The assembly in the asymmetric unit of p15-Δ120 resem-
bled the interface 2 observed with the full-length protein.
However, this interaction does not involve the main chain
of the Arg118 of both molecules, as with the full-length
protein, but instead involves the side chain of residues
Arg118 of chain A with the side chain of residue Glu79 of
chain B of p15-Δ120. This results in a shift between the
two chains, with a displacement of centroid distances of
approximately 6 Å and a rotation of approximately 11° of
the chain B of p15-Δ120 compared to the symmetric
chain of the full-length protein in interface 2 (Figure 7A).
As expected, interface 1 is no longer present in the crystal
packing of p15-Δ120 as the C-terminal residues involved
in this interface with the full-length protein were trun-
cated. However, Trp37, which was involved in the hydro-
phobic interaction with Pro131 in interface 1 (Figure 5A),
is not free in the p15-Δ120 crystal. Instead, this conservedresidue (Figure 4) demonstrates hydrophobic interactions
with a PEG fragment from the crystallization solution in
both monomers of the asymmetric unit (Figure 7B). This
interaction, stabilized by hydrogen bonds between Arg40
and the PEG chain, buries an area of 232 Å2. The presence
of this PEG interaction with Trp37 in place of the C-
terminal end of full-length FIV p15 suggests that this
residue could represent a platform for hydrophobic
interactions with FIV p15.
Finally, the interface 3 observed in the full-length pro-
tein is maintained in the crystal packing of p15-Δ120 with
a similar buried surface and intermolecular interactions as
the full-length protein (Additional file 1: Figure S2C).
In order to investigate the crystal assembly, we
constructed a mutated form of the truncated p15 protein
with the long basic Arg40 residue, which is observed in
the crystallographic interfaces 1 and 3, mutated to a short
polar serine residue to remove the terminal interacting
NH2 of Arg40(p15-Δ120-R40S). Cross-link experiments
showed that this mutant was still able to generate dimers
in solution in MES buffer (Figure 8A). Because none of
the crystallographic interfaces could be linked to the
known properties of retroviral matrix proteins and to the
biochemical data obtained with our constructs in vitro, we
wondered whether the dilution of the protein in the
crystallization condition could have altered the dimeric
interface. The presence of a high concentration of PEG in
the solution did not allow us to investigate the presence of
a dimer using MALLS, DLS or ITC experiments because
of the viscosity of the sample. However, cross-linking
experiments demonstrated that the dimer of full-length
p15, although stable in MES pH 6, dissociates when mixed
to the crystallization condition to become a monomer
(Figure 8B). This dissociation of the dimer was not due to
an interference of the crystallization condition with the
cross-linking agent, as control dimeric proteins were still
cross-linked in the crystallization condition of p15
(Additional file 1: Figure S1B). We therefore investigated
which component of the crystallization condition (0.2 M
Figure 5 Crystal-packing interfaces of FIV p15 generated by PISA. (A) Interface 1 implicating the Trp37 residue in an interaction with the C-terminal
end of p15. (B) Interface 2 implicating C-terminal antiparallel regions. (C) Interface 3 implicating residues from h2, h4, h5 and l3. N- and C-termini are
indicated, and helices are numbered h1 to h5 with a coloring scheme identical to Figure 2A. The hydrogen bonds are displayed as dashed lines.
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sible for this dissociation. Incubation of p15 with 0.2 M
sodium acetate pH4.6 alone did not dissociate the
dimer, excluding a role of the pH on p15 dimer dissoci-
ation (Figure 8B). On the opposite, the presence of high
concentrations of PEG (>10% w:v, Figure 8B) was associ-
ated with the disappearance of the dimeric form. It has to
be noted that the behavior of p15-Δ120 in its own
crystallization condition was not tested because it contains
Tris that interferes with BS3 cross-linking.Discussion
FIV p15 dimerization is pH and concentration dependent:
influence on myristoyl group exposure
To our knowledge, this study is the first to characterize
the oligomeric forms of FIV p15, using a combination of
dynamic light scattering (DLS), chemical cross-linking,
and SEC-MALLS experiments. Our results demonstrate
for the first time that the oligomeric state of FIV p15 is
dependent both on protein concentration and on the
buffer used. The dimerization of FIV p15 protein at high
Table 3 Intermolecular contacts in the crystallographic interface for full-length FIV p15
Interface Buried area per monomer Interacting residues and atoms
(first monomer)
Interacting residues and atoms
(second monomer)
Distance (Å)
Interface 1 543 Å2 Arg40-NH2 Glu129-OE1 2.2
Lys28-NZ Gln133-OE1 2.3
Asn34-NH2 Gly130-O 2.9
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from the reported trimerization of HIV p17 [13].
Here, we provide evidence that the oligomeric state of
the non-myristoylated FIV p15 protein is modulated by
pH. The monomeric protein shifts to a dimeric form
when the pH decreases. This dimer was stable as dem-
onstrated by its dissociation constant around 10 μM as
measured by ITC. These results support the hypothesis
that deprotonation, by increasing the pH to 7.4, inhibits
the formation of oligomers for FIV p15, as previously
observed in the case of myristoylated HIV p17 [38].
Intracellular pH often fluctuates (from 6.3 to 7.8) in
response to cell growth, development and apoptosis [39-41]
and varies in sub-cellular compartments. In particular, a
significant decrease in pH from 7.2 to as low as 6.0 has
been observed in cells infected by HIV [42]. This acidifica-
tion could initiate the multimerization of Gag at the end
stage of the viral cycle to lead to viral particle assembly.
At early stage of replication (i.e. after virus entry in a cell
with a more neutral pH), deprotonation would lead to a
shift towards a monomeric form of p15 during the release
of the viral core in the infected cell. Therefore, the matrix
protein could act as a “pH sensor” implicated in a pH-
dependent assembly and disassembly of retroviral parti-
cles. Such a role of pH variations in Gag oligomerization
remains to be confirmed in cellulo.
The oligomeric state of the FIV p15 protein is also
concentration-dependent in vitro. In the case of HIV, it is
thought that the Gag polyprotein is primarily monomeric
at low concentrations and is therefore largely cytoplasmic
because of the sequestration of the myristoyl group [43].
As its concentration increases, a greater fraction of Gag is
driven into multimeric forms, resulting in myristoyl
exposure and efficient membrane binding. The virus
might exploit this mechanism to confine Gag polyproteins
in specific cellular locations [38]. However, the myristoyl
switch mechanism is significantly different for the matrixproteins of HIV-1, HIV-2 and EIAV [31,44], indicating that
key differences in the myristoyl switch mechanism may
exist [38]. This mechanism could also be different for FIV.
According to docking experiments, the insertion of the
myristoyl group in the hydrophobic pocket of FIV p15 is
possible, with similar binding free energy compared to the
estimation based on the structure of HIV myristoylated
p17, and involves residues at the same positions. However,
the sequestration of the myristoyl group in FIV p15 is
associated with the motion of the side chain of Trp9,
which is involved, in turn, in an aromatic stacking against
of the Phe35 and Phe90 side chains. These aromatic resi-
dues are absent in HIV but well conserved between circu-
lating FIV strains, with Phe90 sometimes substituted with
another aromatic residue (Tyr), suggesting the importance
of this aromatic stacking for the function of p15. More
experiments should be performed to evaluate if the
sequestration of the myristoyl for FIV p15 involves an
aromatic switch, which would represent specificity for FIV
p15 compared to HIV p17.
Another feature revealed by the docking experiments
is the possibility for the myristoyl group to bind in a
groove at the surface of FIV p15. This groove involves
residues Asp8, Ala12, Glu55, and Leu95, which are
highly conserved between FIV strains. Moreover, this
groove is also present in the structure of the HIV MA
protein [21]. It is noteworthy that the residues Leu8,
Glu12, Glu52 and His89 of HIV p17, located at the same
position as those of FIV p15 predicted to interact with
the myristoyl group, are present in the groove of HIV
p17 and conserved among HIV strains [45]. Although an
NMR study of myristoylated HIV p17 did not reveal this
conformation of the myristoyl group [21], the presence
of this groove in both structures, involving conserved
residues in both viruses, could reflect a common role for
this groove in accommodating the myristoyl group across
lentiviral species; for example during the decapsidation
Figure 7 Comparison of FIV p15 structures. (A) Superimposition
of the structure of p15-Δ120 (chain A in blue, chain B in cyan) with
interface 3 in the full-length p15 crystal (chain A in red, symmetric
molecule in magenta). The superimposition was performed on the
Cα of both chains A using COOT. N- and C- termini are indicated for
each chain. (B) The close-up view of the interaction of the PEG
molecule (magenta) with the Trp37 and Arg40 residues of p15-Δ120.
Figure 6 Crystal structure of p15-Δ120. The color scheme of the
two p15 subunits is identical to Figure 2A. N- and C-termini are
indicated, and the helices are numbered h1 to h5. The two PEG
molecules are displayed in magenta.
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leaflet of the plasma membrane to participate in the
formation of the preintegration complex.Structural specificities of the C-terminus of FIV p15
We have determined the crystal structure of the FIV p15
full-length protein and of a form that lacks its C-terminal
end (p15-Δ120). Both structures are similar, with a RMSD
of 0.5 Å between Cα pairs. Like the MA proteins of other
lentivirus, the FIV p15 protein has five α-helices. However,
these helices have different lengths compared to the
published structures of the lentiviral MA proteins for
HIV [13], SIV [32], and EIAV [31]. The structure of the
full-length FIV p15 allowed us to observe in the electron
density maps the complete C-terminus of the protein up to
residue 134, and only residues 2 and 3 of the N-terminuswere missing for the full-length protein. However, these
N-terminal residues 2 and 3 were visible in the structure
of the truncated form p15-Δ120.
As stated above, we were able to observe the complete,
extended C-terminal end of the full-length FIV p15 due
to crystal contacts between Pro131 and Trp37 of the
complementary monomer. One cannot exclude a possible
influence of the C-terminal histidine tag on the flexibility
that we observe for the C-terminal region of p15. However,
this seems unlikely for two reasons. First, the protein
without the 6-His tag displayed the same biochemical
properties in solution than with the tag, as demonstrated
by cross-link experiments. Second, the presence of the
His-tag does not modify the structure of the C-terminal
region in the truncated form p15-Δ120 compared to the
full-length protein. The structure of the C-terminal end
appears to be an important feature for retroviral matrices
as it differs depending on the virus. Indeed, the C-
terminal region following helix h5 is extended in the FIV
p15 structure, which is in line with what has been demon-
strated for EIAV [31], where the flexible C-terminus is not
observed in the electron density map. In contrast, a struc-
tured C-terminus with a short β-hairpin is observed in
A M 1 2
B









Figure 8 Investigation of p15 dimer formation. (A) Chemical cross-linking with BS3 of p15-Δ120-R40S at 6 mg/ml in 50 mM MES pH 6 buffer
in the absence (lane 1) or presence (lane 2) of BS3. (B) Chemical cross-linking of p15 with BS3 in the presence of MES (lane 2), crystallization
condition 25 of PEG suite (0.2 M sodium acetate pH 4.6, 20% w:v PEG 3350, lane 3), sodium acetate 0.2 M pH 4.6 (lane 4), and 2.5%, 5%, 10% and
20% w:v PEG 3350 (lanes 5 to 8 respectively). Lane 1 is the negative control of p15 without BS3.
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(Figure 3). However, the structures of HIV MA, as deter-
mined by NMR (PDB ID: 1HMX and 1TAM), indicate
that this region is disordered [30,46]. Thus, the extended
conformation of the FIV p15 C-terminus could represent
a biological feature of the protein, and the well-ordered
structures of the HIV and SIV p17 C-terminus could
represent crystallization artifacts [47]. This is underlined
by the fact that the C-terminal portion of MA is not
compactly folded in Gag virus-like particles [48,49]. In
such particles, it is projected into the external environment
and used for the connection between MA and CA in the
Gag polyprotein. Although it is not essential for the
self-assembly process of Gag precursor molecules [50],
this extended C-terminal region of MA could be necessary
to grant accessibility to the viral protease that cleaves Gag
between MA and CA during the maturation of the virus.
Finally, it has been shown that the C-terminal end of HIV
MA may be implicated in the early steps of the viral life
cycle [51]. Therefore, the flexibility of this end may beinvolved in the destabilization of viral particles after virus
entry into the cell.
Crystal contacts reveal potential interactions platforms in
FIV p15
Unlike SIV, HIV and EIAV MA, FIV p15 appears
monomeric in the crystal, although it is dimeric in the
protein solution used for crystallization. We could
demonstrate that this monomerization of p15 during
crystallization was linked to the dissociation of the
dimer in the presence of PEG in the crystallization
condition. Therefore, it is not clear how the crystallo-
graphic contacts we observe might participate to the
biological dimer. For example, we demonstrated a shift
from a monomer to a dimer in MES buffer at pH 6 but not
in phosphate buffer at pH 7.4. This suggests charged resi-
dues in the interface of the biological dimer in solution.
Unfortunately, the three interfaces that we observed in the
crystal involved charged residues that are conserved
among FIV strains. It is therefore not possible to
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conservation between FIV strains or differences in their
protonation susceptibility.
However, several conclusions can be drawn from the
analysis of the three FIV p15 interfaces that were identi-
fied in the crystals. In interface 1, Trp37 is implicated in
the interaction with C-terminal Pro131 of the comple-
mentary monomer (Figure 5A). This Trp residue is
highly conserved among lentiviral species and has been
shown to be implicated in the dimer interface of EIAV MA
[31]. For HIV and SIV MA, this residue is accessible to the
surface of the protein, allowing potential interactions with
biological partners. This might also apply to FIV p15 where
Trp37 is exposed and participates in contacts with a
symmetric protein in the full-length FIV p15 protein
crystal (Figure 5A). When deleting the C-terminal region
that interacts with Trp37 in the p15-Δ120 construct, the
deleted C-terminus is replaced in the crystal of the trun-
cated p15-Δ120 by a PEG molecule, which interacts with
this tryptophan (Figure 7B), suggesting that this residue
represents a strong hydrophobic interacting platform for
FIV p15. This binding of a fragment of PEG to this region
might also provide the basis of our observation that PEG
dissociates p15 dimers in vitro. This suggests that this
hydrophobic platform around Trp37 could be involved
in the formation of the p15 dimer, which would be
destabilized by a PEG molecule that would compete
with a p15 monomer for binding to this platform. Previous
studies have shown that this Trp contributes to the PI(4,5)
P2 binding site of HIV MA [44]. Moreover, the mutation
of this residue in the case of the HIV totally abolishes
the assembly of viral particles, suggesting structural
implications for this residue in the matrix protein [52].
Hydrophobic Trp-Pro interactions have also been described
in protein/protein interactions during HIV replication, for
example in the interaction of HIV CA with cyclophilin A
[53,54]. Thus, in the case of FIV p15, Trp37 could be a
platform for p15 dimerization, binding of PI(4,5)P2 and/or
binding of other proteins such as those involved in the
pre-integration complex (PIC). Although the mechanism
whereby the MA protein is recruited into the PIC and
contributes to nuclear import remains unclear, it has been
shown that the C-terminal residues of HIV MA can interact
with the integrase protein [55]. The influence of the FIV
p15 C-terminal domain in the formation of the PIC during
FIV replication should therefore be investigated. However,
although interface 1 suggests the importance of Trp37 for
the function of the FIV p15 protein, the residue is not
involved in the biological dimeric interface of p15 as
demonstrated by the detection of matrix dimers for the
truncated p15-Δ120 protein that lacks the Pro131
interacting with Trp37.
In interface 2, an antiparallel interface, involving
residues Thr117, Arg118 and Pro119 and their symmetry-related counterparts, is observed at the center of the
dimer interface for the full-length protein but is less tight
for the truncated p15-Δ120. It should be noted that SIV
also displays an antiparallel interface at its C-terminal
end, but this interface is intramolecular, leading to the
formation of a C-terminal β-hairpin. It would be interesting
to investigate the role of such an antiparallel interaction in
the function of retroviral matrix proteins.
A third dimeric interface was identified in FIV p15
crystals, both in the full-length protein and the trun-
cated p15-Δ120. At first glance, interface 3 resembles
the interface found in the EIAV dimer [31], with the
orientation of the two N-terminal regions in the same
direction and the involvement of helices h2 and h5
(Additional file 1: Figure S2). However, it displays several
differences. Indeed, EIAV presents a dimeric interface
along a 2-fold axis, with a slight rotation between the
two monomers resulting in curved crystal packing [31],
but interface 3 of FIV p15 results from a translation of
one monomer to the next monomer (Figure 5C). However,
this is the only interface of FIV p15 that i) is observed in
both full-length and p15-Δ120 crystals, ii) is not modified
by the C-terminal truncation of FIV p15, and iii) orients
the N-terminus (and therefore the myristoyl group) and
the basic patch of helix h1 towards the same orientation
as the two monomers of the dimer. According to the
model of HIV assembly, this concerted orientation is the
only one that would allow the simultaneous interaction of
both monomers with the internal surface of the plasma
membrane and permit the radial arrangement of Gag
polyprotein during virus assembly. Interestingly, the buried
surface area of this interface (401 Å2) is similar to the
buried surface area (410 Å2) of the protein interface
leading to the formation of the SIV trimers [32].
In the absence of native dimers in the crystal structures,
due to the dissociation of p15 dimers by the PEG present
in the crystallization condition, a specific and systematic
mutagenesis study will need to be performed to identify
the residues involved in the formation of the dimers. The
elucidation of the biological dimeric interface of FIV p15
is important, as dimers of FIV p15 proteins could repre-
sent intermediates in the biological multimerization of
Gag polyproteins into hexamers. Previous data indicates
that although HIV MA proteins form 3D crystals as
trimers [13], no matrix trimers were visible by electron
microscopy analysis and fitting a trimer unit into the
hexameric projection structure was difficult to achieve,
suggesting that matrix hexamers rather than trimers are
the fundamental unit of HIV particles [26]. Three MA
dimers could fit in the hexameric model, suggesting that
the dimeric form could represent a potential biological state
of the matrix protein. An electron microscopy analysis
of p15 rearrangements in FIV immature particles and
the replacement of the FIV p15 structure in the 3D
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involved in the formation of the viral matrix and confirm
this model.
Conclusion
In summary, the dimeric form of FIV p15 in solution and
its extended C-terminal end in the crystal structure are
original features of this protein when compared to HIV,
SIV and EIAV. Although the dimeric interface remains
to be identified, the presence of a Trp residue as an
interacting platform is likely important for the function
of FIV p15. Further study of these characteristics will be
needed to better understand their biological relevance
in the context of FIV replication and their peculiarity
among lentiviral matrix proteins.
Methods
Plasmid constructs
The FIV p15 open reading frame of the Petaluma strain
(GenBank accession number: M25381.1) was amplified
from 0.1 μg of the plasmid FIV-34TF10 obtained
through the NIH AIDS Research and Reference Reagent
Program.
For the PCR amplification of the full-length protein,
we used the forward primer (5'-CATATGGGGAATGG
ACAGGGGCGAGATTGG -3', NdeI site underlined),
and the reverse primer (5’-AGATCTTCAATGATGATG
ATGATGATGCTCGAGTGAACCTCTTGG-3') using the
Phusion PCR kit (Finnzyme) according to the manufac-
turer’s protocol, with 25 cycles of PCR and a hybridization
temperature of 50°C. A truncated form of the p15 protein
(p15-Δ120) was obtained using the same procedure, with
reverse primer 5’-GCTCGAGTGAACCTCTTGGAACC
AGAGATGGCCTAGTGTCTAATC-3’. A second PCR
round was performed on all constructs with the same
forward primer and with reverse primer 5'-AGATCTT
CAATGATGATGATGATGATGCTCGAGTGAACCTC
TTGG-3' introducing the Bgl2 site (underlined) as well
as a C-terminal 6-His Tag. The PCR products were
digested with NdeI and Bgl2 and inserted into the MCS of
the pRSET-B prokaryotic expression vector (Invitrogen)
digested with the same enzymes. This creates the pRSET-
p15 expression plasmid for our p15 constructs that
encode proteins with a 6-His tag at the C-terminal end of
the protein. The plasmids were transformed into E. coli
BL21(DE3)pLysS cells (Lucigen) for protein expression.
Expression of His-tagged p15
Cells transformed with pRSET-p15 were grown at 37°C in
Hyper Broth (HB) medium (AthenaES™) supplemented
with 25 μg/ml of Ampicillin. Transformed cells were
grown up in 10 ml of HB for 20 h at 37°C with agitation.
This over-grown culture was then added to 1 L of HB
supplemented with 25 μg/ml of Ampicillin in a 5 L baffledflask. Cell growth was monitored by optical density (OD)
measurements at 600 nm. When culture reached an
OD600 of 0.6, expression of FIV p15 proteins was induced
by the addition of isopropyl-β-D-thiogalactopyranoside
(IPTG, Euromedex) to a final concentration of 2 mM.
After 20 h of induction at 25°C, cells were collected by
centrifugation at 10,000 × g for 8 min, and the wet pellet
was stored at -20°C overnight.Purification of His-tagged p15
Two steps of purification were performed to purify FIV
p15 proteins: a nickel affinity followed by a size exclusion
chromatography.
A total amount of 10 g of frozen cell pellet from 1 L
culture was resuspended in LEW buffer (Lysis-Equilibra-
tion-Wash, 50 mM NaH2PO4, 300 mM NaCl), pH 8,
with lysozyme (Sigma) to a final concentration of 1 mg/ml,
anti-protease cocktail 1X (Halt™ Protease Inhibitor Cock-
tail, Thermo Scientific) and DNase I (Sigma) at 2U/ml
final, for 1 h on ice. Then, the resuspended pellet was
pushed 3 times through a high-pressure chamber, using a
microfluidizer M-110P (Microfluidics) at 17,000 psi. The
bacterial lysate was clarified by centrifugation at 10,000 ×
g for 20 min, and the supernatant was filtered through a
0.45 μm membrane. The supernatant was loaded into
gravity column packed with 2 g of Ni2+-TED resin
(Macherey-Nagel) and eluted with LEW buffer pH 8
containing 50 mM of Imidazole, after 3 washes with LEW
buffer pH 8. For gel filtration chromatography, the
samples from the affinity chromatography containing the
p15 protein loaded on a Vivaspin-PES-5 K filter (Sartorius)
and centrifuged at 7,000 × g at 4°C until it reached the
volume of 10 ml. The gel filtration experiment was then
performed in a FPLC system (Äkta purifier, GE Healthcare),
using a Superdex 75 TM Hiload 26/60 column (GE
Healthcare) and a buffer containing 50 mM sodium
phosphate pH 7.4 or 50 mM MES pH 6, in one injection
of 10 ml.
His-tagged p15 protein purification fractions were
quantified by measuring the absorbance at 280 nm,
using a Nanodrop. The identity and the purity of the
protein were assessed by SDS-PAGE analysis. Protein
was concentrated using a Vivaspin-PES-5 K filter
(Sartorius) and centrifuged at 7,000 × g at 4°C until the
desired concentration was reached.Removal of the 6-His-tag
Purified protein at 1 mg/ml in phosphate buffer was
digested overnight at 19°C with 10U of thrombin (Sigma)
per mg of protein. After proteolysis, the reaction mix was
loaded twice on a Ni-NTA centrifugation column (Proteus)
according to the manufacturer’s protocol and the flow-
through were collected and pooled. Buffer exchange and
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above for the His-tagged protein.Dynamic Light Scattering (DLS)
Purified protein in 50 mM phosphate buffer at pH 7.4
or 50 mM MES buffer at pH 6 was concentrated to 4
and 6 mg/ml respectively by using a Vivapsin-PES-5 K
centrifugal concentrator (Sartorius). The DLS experiment
was realized on a dynamic light scattering Zetasizer Nano-S
ZEN1600 instrument (Malvern Instruments) at 20°C. The
samples were previously filtered through a 0.02 μm pore
size filter (Nalgene). Each measure is the mean of 12 runs
and was repeated three times.Chemical cross-linking
Purified p15 proteins at high concentration (6 mg/ml in
50 mM phosphate buffer at pH 7.4 or 6 mg/ml in
50 mM MES buffer at pH 6) and at lower concentration
(3 mg/ml in 50 mM phosphate buffer at pH 7.4 or
3.3 mg/ml in 50 mM MES buffer at pH 6) were mixed
with a cross-linking agent, the Bis(SulfoSuccinimidyl)
Suberate (BS3, Pierce). Reaction mixtures containing
7 μg of proteins were incubated with 1 μl of 5 mM BS3
(corresponding to a 20:1 (w:w) BS3:p15 ratio) for 30 to
45 minutes at room temperature. The reaction was
stopped by addition of 1.5 μl of 250 mM Tris-HCl pH 7.5,
30 mM Glycine for 15 minutes at room temperature, and
adjusted to a final volume of 10 μl. Cross-linked proteins
were denatured by addition of Laemmli sample buffer and
cross-linked proteins were submitted SDS-PAGE analysis.
To assess the impact of the crystallization condition, p15
proteins at 6 mg/ml in 50 mM MES buffer pH 6) were
mixed to crystallization condition, 0.2 M sodium acetate,
or increasing concentration of PEG with a ratio 1:1. Control
was performed by mixing the protein with MES buffer only
with the same ratio 1:1. Murine antibody 11H6H1 [56] and
FIV capsid protein p24 [57] were used as control proteins
for BS3 cross-linking in the crystallization condition.SEC-MALLS experiments
To verify the oligomeric state of the protein in solution,
FIV p15 was analyzed using a SEC-MALLS (size-exclusion
chromatography with multi-angle laser light scattering).
We loaded 0.2 ml samples of p15 protein at 6 mg/ml in
50 mM MES pH 6, onto a Superdex 200 10/30 gel-
filtration column equilibrated at 0.5 ml/min with 50 mM
MES pH 6. The eluate was passed successively through a
MiniDawn TREOS-angle light scattering detector (Wyatt)
coupled to an Optilab T-rEX refractive index monitor
(Wyatt). The data were processed, and molecular masses
were calculated using the Astra V software (Wyatt).Isothermal Titration Calorimetry (ITC) and estimation
of the Kd
Dilution experiments were conducted as described
previously [57] to investigate the dissociation process
of the dimer-to-monomer transition using an ITC200
calorimeter (GE Healthcare). Briefly, protein samples of
FIV p15 at 6 mg/ml (375 μM) into 50 mMMES pH 6 were
used for sequential injections of concentrated protein
solution (injection #1: 1.5 μl and injections #2-16: 2.5 μl),
spaced at 120 seconds intervals, into the calorimetric cell
(200 μl), which initially contained buffer alone (50 mM
MES pH 6). Measurements were performed at 25°C, and
data were analyzed using a dissociation model in the
Origin software according to the manufacturer's instruc-
tions (GE Healthcare). The first data point was excluded in
the analysis. The binding parameters ΔH (reaction enthalpy
change in cal/mol) and Kd (dissociation constant in mM)
were allowed to float during the fit.
Crystallization of the FIV p15 protein and data collection
Crystallization conditions were searched using the sitting-
drop vapour-diffusion method and commercial kits from
Hampton Research, Molecular Dimensions Limited (MDL)
and Qiagen. Crystals of FIV p15 were obtained by equili-
brating drops of protein (concentrated at 7 mg/ml in
50 mM MES buffer pH 6) mixed 1:1 with the condition
25 of the Qiagen PEGs Suite, consisting of 0.1 M sodium
acetate pH 4.6 and 25% (w:v) polyethylene glycol (PEG)
3,000 at 16°C. Tiny rod-shaped crystals with maximum di-
mension 60 × 30 × 10 μm3 were obtained within fifteen
days. Crystals were transferred to a cryoprotective solution
containing the mother liquor and 10% (v:v) ethylene glycol
for 30 sec and plunged into liquid nitrogen prior to data
collection. First grown crystals diffracted at best to 3 Å
resolution at the SLS beamline PXIII (Villigen PSI,
Switzerland) and at the ESRF beamline ID23-2 (Grenoble,
France) under cryo-conditions (100 K). Microseeding was
necessary to optimize crystals and the best dataset was
collected at 100 K to 2 Å resolution at the SOLEIL
beamline Proxima 1 (Paris, France). A new crystallization
condition was determined for the p15-Δ120 construct.
Crystals were obtained in 0.1 M Tris pH 8, 25% (w:v) PEG
6000 (condition 45 of the Qiagen PEGs suite). Crystals
were harvested as for the full-length protein and data were
collected at 100 K to 2.7 Å resolution at the ESRF
beamline ID29.
Structure determination of FIV p15 and refinement
Diffraction intensities were processed with the programs
XDS [58] and XSCALE. The structure of full-length p15
was determined by the molecular replacement method
using the program MrBUMP [59] of the CCP4 program
suite and the structure of SIV matrix protein (PDB ID:
1ECW) as the search model. Final automated building
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the residues present in the final model. Crystallographic
refinement was performed with PHENIX [61] and
residues 119-129 were built manually using COOT [62].
The final model is made up by one copy of FIV p15
(chains A, residues 4-133), 4 molecules of ethylene glycol
and 28 water molecules. The model shows a good
geometry with 2 glycine residues as Ramachandran out-
liers. Figures were generated with the PyMOL software
from Schrödinger. The electrostatic potential map and
the molecular surfaces were calculated using DelPhi
[63]. Structure of p15 truncated mutant p15-Δ120 was
determined using the full-length p15 structure as a lead.
The 2 N-terminal residues of p15 could be manually
reconstructed using COOT. Two PEG molecules were
identified and positioned in the electron density maps
using PHENIX and the 7PE ligand coordinates from the
PDB as a template. The final model is made up by two
copies of p15-Δ120 (chains A and B, residues 2 to 120),
2 molecules of PEG (chains P and Q) and 24 water
molecules. This structure shows a good geometry with
no Ramachandran outlier. Statistics of the X-ray data
are provided in Table 1.Docking studies
Molecular docking of the myristoyl group (as ligand)
against p15 crystal structure (the receptor) was done using
molecular docking program AutoDock 4.2.3 [64,65]. Both
molecules were prepared with AutoDockTools 1.5.4 [65]
by adding all essential hydrogen atoms and assigning
Gasteiger charges. All the 12 active torsions of the ligand
were taken into account for the subsequent calculations.
Finally, 6 amino acid residues were defined as flexible for
the receptor, namely Trp9, Cys16, Phe35, Ile39, Ile53 and
Phe90. A grid box of dimensions of 20 × 20 × 20 Å3 (with
a grid spacing of 0.159 Å), large enough to encompass the
pocket, was calculated using the AutoGrid program.
Lamarckian genetic search algorithm was employed and a
maximum of twenty-five million energy evaluations was
performed. After docking completion, solutions were
ranked and sorted according to their docked energy using
the built-in clustering function. Detailed inspection of
the ligand-receptor interactions was carried out with
AutoDockTools.Alignment of sequence of retroviral matrix proteins
The sequences alignment between retroviral matrix pro-
teins was carried out using the web tool ESPript/ENDscript
[66,67]. The best structural homologues are the EIAV
p15 protein (PDB ID: 1HEK), the HIV p17 protein (PDB
ID: 1HIW) and the SIV p17 protein (PDB ID: 1ECW)
with 21%, 18% and 11% of sequence identity with the
FIV p15 protein.Availability of supporting data
The coordinates and the structure factors are deposited in
the Protein Data Bank [68] under the accession numbers
4IC9 and 4ICA for the full-length FIV p15 and p15-Δ120,
respectively.
Additional file
Additional file 1: Figure S1. (A) Cross-linking experiment on p15-
Δ120 in MES buffer pH 6 at 3 mg/ml (lane 1 & 4) or 6 mg/ml (lane 2 & 5)
in the absence (lanes 1–2) or the presence (lanes 4–5) of cross-linking
agent BS3. Lane 3: molecular weight marker. (B) Chemical cross-linking
with BS3 of control protein FIV p24 [57] in its own buffer (lane 1) or
crystallization condition of p15 (0.2 M sodium acetate pH 4.6, 20% w:v
PEG 3350, lane 2). Lane 3: molecular weight marker. The asterisk indicates
the expected size for the dimeric forms for each protein. Figure S2:
Comparison of the dimeric interface of EIAV (A) with the interface 3 of
full-length p15 (B) and p15-Δ120 (C). The color scheme is identical to
Figure 2A.
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